Controversial former pharmaceutical CEO Martin Shkreli may face more charges connected to his role in a biopharmaceutical company.

A prosecutor in the case said during a hearing Tuesday that Shkreli could face additional charges of securities fraud, several media outlets reported. Shkreli caused a public outrage last year when his former company, Turing Pharmaceuticals, drastically raised the price of an anti-malarial drug it bought by 5,000 percent.